Almac: selectAZyme(TM) Grows into Metabolite Synthesis
Product News Feb 14, 2012
"Biocatalysis is now Almac's first choice for any scale-up chemistry involving chirality resulting in cheaper, cleaner and robust processes" says Head of Biocatalysis, Dr. Tom Moody.
Metabolite synthesis is another tool within the selectAZyme(TM) service offering that Almac has developed significantly in recent years, providing access to both oxidative and glycosylated products. Recombinant and microbial P450 and glycosylating technology have been developed for accessing metabolites at mg to 100s grams scale. These enzymes mimic human systems and are a powerful tool for accessing metabolites rapidly and efficiently, typically in one step from the parent API.
Almac's biocatalyst technology platform is well represented by the green selectAZyme(TM) logo emphasising the "green" credentials the technology offers, from medicinal chemistry scaffold and metabolite synthesis through to commercial manufacture.
The application of biocatalysis results in reduced energy costs, lowered impact on the environment and efficient multi-tonne processing in timelines comparable to traditional chemistry.
Future plans involve discovery and development of novel P450 and transaminase enzymes using metagenomic techniques which will significantly enhance and differentiate the portfolio of enzymes currently available to Almac and its customers.
If your process requires "greening" up, contact Almac's biocatalysis group.